Is Now the Time to Add Vipshop Holdings to Your Portfolio?

NYSE: VIPS | Vipshop Holdings Ltd. ADR News, Ratings, and Charts

VIPS – Vipshop Holding (VIPS), an under-the-radar Chinese e-commerce stock, is well-positioned to see gains in the upcoming months due to a strong macroeconomic recovery and weakening competition from industry leaders. Because consumer demand in China is recovering swiftly, VIPS’ should witness a rush of orders this holiday season and beyond, which will boost its revenue and earnings.

Vipshop Holdings Ltd. (VIPS) is a discount e-commerce retailer operating in China. The company is known for its discounted flash sales of a limited number of branded products. As its main competitors Alibaba Holdings Group Ltd. (BABA) and JD.com, Inc. (JD) are currently under government scrutiny, VIPS has the opportunity to grow significantly as a leading player in the Chinese e-commerce industry.

Following the recent anti-trust regulation draft released by the Chinese government, BABA’s shares declined 15.9% over the past month, while JD gained 2.5%. This compares to VIPS’ 17.7% rise over the same period.

With manufacturing and services sectors in China growing significantly over the past couple of months, strengthening consumer demand should lead to revenue growth for VIPS this holiday season and beyond. The stock has gained 77.4% year-to-date. This impressive performance and potential upside is based on several factors that have helped VIPS earn a “Strong Buy” rating in our proprietary POWR Ratings system.

Here’s how our proprietary POWR Ratings system evaluates VIPS:

Trade Grade: A

VIPS is currently trading above its 50-day and 200-day moving averages of $21.87 and $19.57, respectively, indicating a golden cross uptrend. It gained 52.4% over the past three months, reflecting solid short-term bullishness.

VIPS’ total revenue increased 18.2% year-over-year to RMB23.20 billion in the third quarter ended September 2020. Gross merchandise volume rose 21% from the year-ago volume to RMB38.30 billion, while net income grew 42.1% from the same period last year to RMB1.20 billion. VIPS recorded 43.40 million active customers during the quarter, up 36% from the prior year quarter.

Buy & Hold Grade: A

In terms of proximity to its 52-week high, which is a key factor our Buy & Hold grade considers, VIPS is well positioned. It is currently trading just 3.6% below its 52-week high of $26.07, which it hit on November 27th.

VIPS gained 198.8% over the past three years. This can be attributed to its impressive growth in revenue and earnings over the same period. VIPS’ revenue and EPS increased at CAGRs of 12.1% and 29.2% respectively, over the past three years. Net income rose at a CAGR of 34% over the same period.

The booming Chinese economy over the past couple of years contributed heavily to VIPS growth. China’s strained relations with the United States diverted attention to domestic companies to meet the rising consumer demand in the economy, thereby generating higher sales for discount retailers such as VIPS. Also, as VIPS’ largest competitor BABA started focusing more on its cloud segment, VIPS attracted a larger number of customers through its aggressive pricing policies.

Peer Grade: A

VIPS is currently ranked #4 out of 115 stocks in the China group. Other popular companies in this group are Baidu, Inc. (BIDU), Yum China Holdings, Inc. (YUMC) and Bilibili, Inc. (BILI).

While BILI beat VIPS by gaining 231.9% year-to-date, BIDU and YUMC returned 13.7% and 17.9% respectively, over the same period.

Industry Rank: B

China group is ranked #36 out of 123 StockNews industries. China’s miraculous recovery from the pandemic has made it the only leading economy to report positive GDP growth this year. With even the developed countries still battling recession coupled with a second wave of coronavirus worsening the economic conditions, most Chinese companies are witnessing strong rebound owing to strengthening consumer demand. With China currently ahead of the rest of the world in terms of growth, betting on companies operating primarily in this economy should be profitable.

Overall POWR Rating: A (Strong Buy)

VIPS is rated “Strong Buy” due to its solid short-and-long-term bullishness, impressive financials, and underlying industry strength, as determined by the four components of overall POWR Rating.

Bottom Line

Analysts expect VIPS’ price to reach $171.26, indicating a 574.2% growth, as the seasonal demand kicks in this month. This, coupled with a weakening market competition amid a fast recovering economy, makes VIPS a good investment bet now.

VIPS has an average broker rating of 1.38, indicating favorable analyst sentiment. Out of 27 Wall Street Analysts that rated the stock, 16 rated it “Strong Buy.” The consensus EPS estimate of $0.48 for the fourth quarter ending December 2020 indicates a 20% rise year-over-year. VIPS has an impressive earnings surprise history as well, as it beat the street EPS estimates in three of the trailing four quarters. The consensus revenue estimate of $5.30 billion for the current quarter indicates a 26.4% improvement from the prior-year quarter.

Want More Great Investing Ideas?

9 “MUST OWN” Growth Stocks for 2021

Are Stocks Off to the Races in December?

7 Best ETFs for the NEXT Bull Market


VIPS shares were unchanged in after-hours trading Thursday. Year-to-date, VIPS has gained 76.99%, versus a 15.56% rise in the benchmark S&P 500 index during the same period.


About the Author: Aditi Ganguly


Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do’s and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
VIPSGet RatingGet RatingGet Rating
YUMCGet RatingGet RatingGet Rating
BIDUGet RatingGet RatingGet Rating
BILIGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

How to Beat the Market the Rest of the Year?

The easy gains that came at the start of this new bull market are fading away fast. In fact the stock market (SPY) has become quite volatile with gains harder to come by. Gladly there are solutions as will be shared in this commentary to get you on the right path to outperform the market through the end of 2021 and beyond. Read the rest below...

:  |  News, Ratings, and Charts

2022 Stock Market Outlook

The stock market (SPY) has continued on a bullish path in 2021. Will that continue in 2022? And what could happen to awaken the bear market from hibernation? 40 year investment veteran Steve Reitmeister explores this and more in this early edition of his 2022 Stock Market Outlook. Read on for full details below...

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

:  |  News, Ratings, and Charts

3 Value Stocks to Buy While You Still Can

After outperforming from last fall into the spring, value stocks have been overtaken by growth stocks, but that is expected to change as the economic recovery continues. So, now is the time to start putting your money to work in undervalued companies that offer the potential for strong returns such as Gilead Sciences Inc. (GILD), HP Inc. (HPQ), and CNH Industrial N.V. (CNHI).

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

Read More Stories

More Vipshop Holdings Ltd. ADR (VIPS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VIPS News